US8597885.pdf (2.64 MB)
Accelerated Progression Relapse Test
standard
posted on 2016-06-07, 00:00 authored by Steven BuechlerAn Accelerated Progression Relapse Test (APRT) is provided for use in the prognosis of a diseased state in a patient. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. In particular applications, the APRT may be used to determine the prognosis of an estrogen receptor positive (ER+) breast cancer patient. Four genetic probes are disclosed for this test, and target MK167, CDC6 and SPAG5 gene products. The ER+ breast cancer patient/patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient/patient group as more likely to benefit from additional treatment measures.
History
Patent Number
US 8597885 B2Other Application
12/695,723Inventor
Steven BuechlerInventor from Local Institution
Steven BuechlerAssignee
University of Notre Dame Du LacDate Modified
2016-06-07Language
- English
Claims
5Prior Publication Number
US 20100196906 A1Publisher
United States Patent and Trademark OfficeCooperative Patent Classification Codes
C12Q 1/6886 (20130101); G01N 33/57415 (20130101); G06F 19/20 (20130101); C12Q 2600/106 (20130101); C12Q 2600/158 (20130101); G01N 2800/56 (20130101); G06F 19/24 (20130101)Contributor
Steven BuechlerInternational Patent Classification Codes
C12Q 1/68 (20060101); C12Q 1/00 (20060101)US Patent Classification Codes
435/6.11; 435/4; 435/6.1;Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC